Bacille Calmette-Guerin Vaccine Market By Age Group (Pediatrics, Adults), By Application (Tuberculosis, Bladder cancer), By End-use (Hospitals, Clinics), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2024-2033
-
50901
-
September 2024
-
300
-
-
This report was compiled by Trishita Deb Trishita Deb is an experienced market research and consulting professional with over 7 years of expertise across healthcare, consumer goods, and materials, contributing to over 400 healthcare-related reports. Correspondence Team Lead- Healthcare Linkedin | Detailed Market research Methodology Our methodology involves a mix of primary research, including interviews with leading mental health experts, and secondary research from reputable medical journals and databases. View Detailed Methodology Page
-
Quick Navigation
Report Overview
The Bacille Calmette-Guerin Vaccine Market was valued at USD 99.5 million in 2023. It is expected to reach USD 170.8 million by 2033, with a CAGR of 5.7% during the forecast period from 2024 to 2033.
The Bacille Calmette-Guerin (BCG) vaccine market encompasses the development, production, and distribution of vaccines designed to protect against tuberculosis (TB). BCG vaccines, derived from a weakened strain of Mycobacterium bovis, are primarily utilized to prevent severe forms of TB in infants and young children, particularly in regions with high TB incidence. This market includes various vaccine formulations and delivery systems, influenced by factors such as global TB prevalence, vaccination policies, and technological advancements in vaccine production.
The Bacille Calmette-Guérin (BCG) vaccine market is poised for notable evolution, driven by several converging factors. Analysts observe a significant increase in the incidence of tuberculosis (TB) worldwide, particularly in regions with high disease burden. This rising prevalence underscores the critical need for effective vaccination strategies, thereby bolstering demand for BCG vaccines.
Moreover, the growing global awareness and expansion of vaccination programs are expected to further stimulate market growth. Governments and health organizations are intensifying efforts to educate the public and expand immunization initiatives, which is anticipated to positively impact vaccine uptake.
However, the market's trajectory is not without challenges. Issues related to vaccine supply and distribution persist, potentially constraining access and affecting overall market performance. Despite these challenges, the BCG vaccine market is on a positive growth trajectory. The combined effect of increasing TB incidence, enhanced awareness, and ongoing vaccination programs provides a robust foundation for market expansion. Analysts predict that addressing supply chain issues and leveraging advancements in vaccine technology will be crucial for sustaining growth and meeting global health objectives. Consequently, the BCG vaccine market is set to experience sustained growth, supported by both rising demand and concerted efforts to overcome existing obstacles.
Key Takeaways
- Market Growth: The Bacille Calmette-Guerin Vaccine Market was valued at USD 99.5 million in 2023. It is expected to reach USD 140.0 million by 2033, with a CAGR of 5.7% during the forecast period from 2024 to 2033.
- By Age Group: Pediatrics dominated the BCG vaccine market, driven by preventive needs.
- By Application: Tuberculosis dominated the BCG vaccine market, driven by prevalence.
- By End-use: Hospitals dominated the BCG vaccine market, followed by clinics.
- Regional Dominance: Asia Pacific dominates the BCG vaccine market with a 60.5% largest share.
- Growth Opportunity: The global BCG vaccine market is set to grow due to expanded use in bladder cancer treatment and improved manufacturing processes, enhancing availability and therapeutic efficacy.
Driving factors
Global Initiatives to Combat Tuberculosis (TB)
Global initiatives aimed at combating tuberculosis (TB) significantly influence the Bacille Calmette-Guerin (BCG) vaccine market. The World Health Organization (WHO) and various global health organizations have intensified efforts to address the persistent burden of TB, which remains one of the top ten causes of death worldwide. These initiatives often include large-scale vaccination campaigns, increased funding for TB control programs, and collaborative efforts between governments and non-governmental organizations.
According to the WHO, an estimated 10 million people fell ill with TB in 2021, demonstrating the critical need for effective vaccination strategies. The focus on TB eradication has driven demand for the BCG vaccine, which is a cornerstone of preventive measures against the disease. The increased investment in TB prevention programs and the promotion of the BCG vaccine contribute to market growth by expanding vaccination coverage and raising awareness about TB control.
Government Immunization Programs
Government immunization programs are pivotal in driving the growth of the BCG vaccine market. Many countries have integrated BCG vaccination into their routine immunization schedules, particularly in regions with high TB prevalence. These programs are designed to provide widespread vaccine access and ensure that populations at risk are adequately protected.
For instance, in countries like India and Bangladesh, where TB incidence rates are high, the BCG vaccine is administered as part of the national immunization program. Such programs not only increase vaccine uptake but also create a steady demand for BCG vaccines. Government-led initiatives often include financial subsidies, distribution logistics, and public health campaigns, all of which contribute to market expansion. The reliance on government programs for vaccine distribution and administration underscores the significant role these initiatives play in the overall growth of the BCG vaccine market.
Advancements in Vaccine Manufacturing Technologies
Advancements in vaccine manufacturing technologies play a crucial role in shaping the BCG vaccine market. Innovations such as improved production processes, enhanced quality control, and the development of more efficient vaccine formulations contribute to market growth by making the vaccine more accessible and affordable.
Recent technological developments in vaccine production have led to increased production capacities and reduced costs. For example, the adoption of modern biotechnological methods and automated production systems has streamlined vaccine manufacturing, resulting in higher output and better quality control. These advancements not only help meet the growing global demand for BCG vaccines but also facilitate the entry of new players into the market, fostering competition and driving further innovation.
Restraining Factors
Supply Concentration and Its Impact on Market Stability
Supply Concentration within the Bacille Calmette-Guerin (BCG) vaccine market is a critical restraining factor that influences market dynamics and growth potential. The production of BCG vaccines is concentrated in a few key manufacturers, which can lead to supply chain vulnerabilities. When production is dominated by a small number of companies, the market becomes susceptible to disruptions due to manufacturing issues, geopolitical tensions, or economic fluctuations affecting these suppliers. For instance, if a major supplier faces production delays or quality control problems, the overall availability of BCG vaccines may be significantly impacted, leading to shortages and higher prices.
This concentration can also hinder market expansion as new entrants find it challenging to compete with established players who control a substantial share of the supply. Furthermore, the reliance on a few suppliers can result in reduced bargaining power for buyers, limiting their ability to negotiate prices and terms. Consequently, this supply concentration can slow down market growth by constraining the distribution network and increasing market volatility.
Limited Product Registration and Market Expansion
Limited Product Registration is another significant factor impacting the Bacille Calmette-Guerin vaccine market. The approval and registration of vaccines are stringent processes that vary from one region to another, affecting how quickly new BCG vaccines can enter the market. Regulatory barriers and extended approval times can delay the introduction of new formulations or production innovations, thereby restricting market growth.
For example, if new BCG vaccine products are not promptly registered or face regulatory hurdles, the market may experience slower adoption rates and limited availability of advanced vaccine options. This limitation can prevent the expansion of the market in regions with high demand or where regulatory processes are particularly rigorous. Additionally, the complexity and cost of navigating different regulatory environments can deter potential new entrants, further consolidating the market and potentially stifling innovation.
By Age Group Analysis
In 2023, Pediatrics dominated the BCG vaccine market, driven by preventive needs.
In 2023, The Pediatrics segment held a dominant market position in the Bacille Calmette-Guerin (BCG) Vaccine Market, specifically within the Age Group segment. This preeminence can be attributed to the heightened focus on tuberculosis prevention in infants and children, as the BCG vaccine is traditionally administered shortly after birth. The prevalence of tuberculosis in pediatric populations, coupled with the vaccine's established efficacy in reducing severe forms of the disease, underpins the significant demand for BCG vaccination in this age group. Governments and health organizations globally continue to endorse the use of BCG for pediatric immunization, contributing to the segment's substantial market share.
Conversely, the Adult segment, while smaller in market share compared to Pediatrics, also plays a crucial role in the BCG vaccine market. The demand within this segment primarily stems from the use of BCG for therapeutic purposes in adult patients with bladder cancer, where it has shown efficacy in reducing cancer recurrence. Although not as predominant as the Pediatric segment, the Adult segment's growth is supported by continued research and the expanding application of BCG in oncology. The market dynamics for adults reflect a more specialized use case, emphasizing the vaccine's versatility and its evolving role in medical treatments beyond tuberculosis prevention.
By Application Analysis
In 2023, Tuberculosis dominated the BCG vaccine market, driven by prevalence.
In 2023, Tuberculosis held a dominant market position in the application segment of the Bacille Calmette-Guerin (BCG) Vaccine Market. Tuberculosis, a persistent global health issue, continues to drive the demand for BCG vaccines due to its high prevalence in both developing and developed regions. The efficacy of BCG vaccines in preventing tuberculosis, particularly in children and individuals with a high risk of exposure, has cemented their essential role in public health strategies. The World Health Organization (WHO) emphasizes BCG vaccination as a critical component of tuberculosis control programs, further bolstering its market presence. Additionally, ongoing initiatives to enhance tuberculosis diagnosis and treatment, along with governmental support for vaccination programs, contribute to the sustained demand for BCG vaccines.
Conversely, the Bladder Cancer application segment also represents a significant portion of the BCG vaccine market. BCG therapy is a standard treatment for superficial bladder cancer, which has been demonstrated to reduce recurrence rates and improve patient outcomes. The growing incidence of bladder cancer, coupled with the effectiveness of BCG as an intravesical treatment, continues to drive market growth in this segment. The increasing adoption of BCG therapy, alongside advancements in treatment protocols and patient management, underscores its vital role in bladder cancer care.
By End-use Analysis
In 2023, Hospitals dominated the BCG vaccine market, followed by clinics.
In 2023, Hospitals held a dominant market position in the end-use segment of the Bacille Calmette-Guérin (BCG) vaccine market. The prevalence of hospitals as the primary end-users can be attributed to their extensive infrastructure and capacity to manage a high volume of vaccinations. Hospitals offer a comprehensive range of services, including diagnostic and therapeutic interventions, which makes them a central hub for BCG vaccination programs, especially in regions with high tuberculosis (TB) incidence. Additionally, the integration of BCG vaccination within hospital settings facilitates efficient patient management and follow-up care, contributing to better overall health outcomes.
Conversely, clinics have also emerged as significant players in the BCG vaccine market, albeit with a different emphasis. Clinics, particularly those focused on primary care and preventive medicine, contribute to the market by offering accessible vaccination services to diverse populations. Their role is increasingly crucial in areas where hospitals may not be as readily available. Clinics provide personalized patient care and often serve as the first point of contact for vaccination, thereby supporting public health initiatives and ensuring widespread BCG vaccine coverage.
Key Market Segments
By Age Group
- Pediatrics
- Adults
By Application
- Tuberculosis
- Bladder cancer
By End-use
- Hospitals
- Clinics
Growth Opportunity
Expanding BCG Vaccine Usage for Bladder Cancer Treatment
The Bacille Calmette-Guerin (BCG) vaccine, traditionally utilized for tuberculosis (TB) prevention, is experiencing an expanded role in oncology, particularly in bladder cancer treatment. The therapeutic use of BCG in treating non-muscle invasive bladder cancer (NMIBC) has shown significant efficacy. The market opportunity is amplified by increasing adoption rates of BCG as a standard of care in bladder cancer management. Clinical studies continue to validate the benefits of BCG in reducing recurrence rates and improving patient outcomes, driving higher demand for the vaccine. This shift towards oncological applications provides a substantial growth opportunity, as healthcare providers seek effective treatments amid rising bladder cancer incidences.
Improving BCG Vaccine Manufacturing Processes
Advancements in BCG vaccine manufacturing processes are further poised to enhance market prospects. Innovations aimed at improving the production efficiency and quality control of BCG vaccines are expected to address supply chain constraints and reduce production costs. Enhanced manufacturing techniques are anticipated to bolster the availability of BCG vaccines globally, ensuring consistent supply to meet growing demand. Additionally, improvements in vaccine formulation and stabilization techniques contribute to longer shelf life and better vaccine performance, which is critical for both TB prevention and bladder cancer treatment.
Latest Trends
Expanding BCG Vaccine Usage for Bladder Cancer Treatment
The Bacille Calmette-Guerin (BCG) vaccine, historically used for tuberculosis prevention, is experiencing a notable shift in its application towards bladder cancer treatment. In recent years, there has been a growing body of evidence supporting the efficacy of BCG therapy for non-muscle invasive bladder cancer (NMIBC). This development is driven by its immunotherapeutic benefits, which have been shown to significantly reduce recurrence rates and improve patient outcomes. As clinical research continues to validate these findings, the use of BCG in oncology is anticipated to expand. This trend is likely to stimulate market growth as healthcare providers and institutions increasingly adopt BCG for bladder cancer management. The expanding use of BCG in this new therapeutic context reflects a broader trend toward repurposing existing vaccines for innovative treatments, a development that may open new revenue streams for manufacturers.
Improving BCG Vaccine Manufacturing Processes
Another significant trend in the BCG vaccine market is the enhancement of manufacturing processes. Historically, the production of BCG vaccines has been characterized by challenges related to consistency and scalability. However, advancements in biotechnological techniques and the implementation of more refined quality control measures are addressing these issues. Innovations such as improved fermentation technologies and optimized formulation processes are expected to enhance the efficiency and reliability of BCG vaccine production. These improvements are poised to address supply chain constraints and meet the growing demand driven by its expanded use in cancer therapy. As manufacturing processes become more streamlined, the overall market for BCG vaccines is anticipated to experience a period of stability and growth, driven by both increased demand and enhanced production capabilities.
Regional Analysis
Asia Pacific dominates the BCG vaccine market with a 60.5% largest share.
The global Bacille Calmette-Guerin (BCG) vaccine market demonstrates significant regional variations, influenced by differing healthcare infrastructures, tuberculosis prevalence, and vaccination policies. As of the latest data, the Asia Pacific region leads the market, commanding approximately 60.5% of the global share. This dominance is attributed to the high incidence of tuberculosis and robust public health initiatives in countries such as India and China, where BCG vaccination remains a critical component of national immunization programs.
In North America, the BCG vaccine market holds a smaller share due to the lower incidence of tuberculosis and the preference for targeted therapy over widespread vaccination. The market is relatively stable, with the United States accounting for the majority of this region's demand. However, advancements in vaccine technology and public health policies continue to influence market dynamics.
Europe represents a diverse landscape with varying levels of BCG vaccine adoption. Countries with higher tuberculosis rates, such as Eastern European nations, exhibit higher market shares compared to Western Europe. The region’s market is also shaped by the European Union's health policies and funding for vaccination programs.
The Middle East & Africa show a growing market potential driven by increasing healthcare access and rising tuberculosis cases in specific countries. Despite challenges in healthcare infrastructure, efforts to enhance vaccination coverage are contributing to gradual market growth.
Latin America, while smaller in market share compared to Asia Pacific, is experiencing steady growth. Countries in this region are bolstering vaccination efforts in response to regional health challenges, thus influencing the market dynamics.
Overall, the Asia Pacific region’s dominance, supported by its substantial share of 60.5%, underscores its pivotal role in the global BCG vaccine market.
Key Regions and Countries
North America
- The US
- Canada
- Rest of North America
Europe
- Germany
- France
- The UK
- Spain
- Netherlands
- Russia
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- Singapore
- Thailand
- South Korea
- Vietnam
- India
- New Zealand
- Rest of Asia Pacific
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- South Africa
- UAE
- Rest of the Middle East & Africa
Key Players Analysis
In 2024, the global Bacille Calmette-Guerin (BCG) vaccine market is characterized by a diverse array of key players, each contributing uniquely to the sector's dynamics.
Merck & Co., Inc. continues to dominate the market due to its extensive research and development capabilities and robust distribution network. The company's established reputation and global reach afford it a significant competitive advantage, enabling it to maintain a substantial market share. Sanofi, another major player, leverages its comprehensive portfolio and advanced manufacturing capabilities. Its strategic focus on enhancing vaccine accessibility in emerging markets complements its established presence in developed regions, thereby broadening its market footprint.
China National Group Corporation (Sinopharm) stands out for its significant contributions to vaccine production and distribution in China and other regions. The company’s strong governmental ties and expansive distribution network facilitate its prominent role in the market. Serum Institute of India Pvt. Ltd. is noted for its large-scale production capacity and cost-effective pricing strategies. This positions it as a key supplier in developing countries, where affordability and availability are critical.
Interfax Ltd. and BCG Vaccine Laboratory are recognized for their specialized focus on BCG vaccines, contributing to innovation and quality assurance within the market. Similarly, Japan BCG Laboratory and Torlak Institute of Virology are important regional players with expertise in BCG vaccine development and production. Other notable contributors, such as AJ Biologics Sdn Bhd, Biomed Lublin S.A., GSBPL, Microgen, Stevens Serum Institute, Taj Pharmaceuticals Limited, and Zydus Group, enhance the competitive landscape through their unique technological advancements and regional strengths.
The competitive landscape of the BCG vaccine market is marked by a blend of established multinational corporations and specialized regional players, each driving growth through innovation, strategic positioning, and market expansion.
Market Key Players
- AJ Biologics Sdn Bhd
- BCG Vaccine Laboratory
- Biomed Lublin S.A.
- China National Group Corporation (Sinopharm)
- GSBPL
- Intervax Ltd.
- Japan BCG Laboratory
- Merck & Co., Inc.
- Microgen
- Sanofi
- Serum Institute of India Pvt. Ltd.
- Stetens Serum Institute
- Taj Pharmaceuticals Limited
- Torlak Institute of Virology
- Zydus Group
Recent Development
- In June 2024, The University of Oxford published results from a clinical trial investigating a modified BCG vaccine with improved efficacy for tuberculosis (TB). The trial demonstrated enhanced immune response and protection against TB, potentially leading to an updated formulation with broader applicability.
- In March 2024, The Serum Institute of India announced a partnership with the World Health Organization to enhance the global supply of the BCG vaccine. This collaboration aims to address the supply shortages in low and middle-income countries and ensure a consistent and reliable distribution of the vaccine.
- In January 2024, UroGen Pharma received FDA approval for a new formulation of the BCG vaccine specifically for the treatment of bladder cancer. This approval expands the therapeutic use of the vaccine and offers a potentially more effective treatment option for patients with high-risk non-muscle invasive bladder cancer.
Report Scope
Report Features Description Market Value (2023) USD 99.5 Million Forecast Revenue (2033) USD 170.8 Million CAGR (2024-2032) 5.7% Base Year for Estimation 2023 Historic Period 2016-2023 Forecast Period 2024-2033 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Age Group (Pediatrics, Adults), By Application (Tuberculosis, Bladder cancer), By End-use (Hospitals, Clinics) Regional Analysis North America - The US, Canada, Rest of North America, Europe - Germany, France, The UK, Spain, Italy, Russia, Netherlands, Rest of Europe, Asia-Pacific - China, Japan, South Korea, India, New Zealand, Singapore, Thailand, Vietnam, Rest of Asia Pacific, Latin America - Brazil, Mexico, Rest of Latin America, Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa Competitive Landscape AJ Biologics Sdn Bhd, BCG Vaccine Laboratory, Biomed Lublin S.A., China National group corporation (Sinopharm), GSBPL, Intervax Ltd., Japan BCG Laboratory, Merck & Co., Inc., Microgen, Sanofi, Serum Institute of India Pvt. Ltd., Stetens Serum Institute, Taj Pharmaceuticals Limited, Torlak Institute of Virology, Zydus Group Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) -
- 1. Executive Summary
- 1.1. Definition
- 1.2. Taxonomy
- 1.3. Research Scope
- 1.4. Key Analysis
- 1.5. Key Findings by Major Segments
- 1.6. Top strategies by Major Players
- 2. Global Bacille Calmette-Guerin Vaccine Market Overview
- 2.1. Bacille Calmette-Guerin Vaccine Market Dynamics
- 2.1.1. Drivers
- 2.1.2. Opportunities
- 2.1.3. Restraints
- 2.1.4. Challenges
- 2.2. Macro-economic Factors
- 2.3. Regulatory Framework
- 2.4. Market Investment Feasibility Index
- 2.5. PEST Analysis
- 2.6. PORTER’S Five Force Analysis
- 2.7. Drivers & Restraints Impact Analysis
- 2.8. Industry Chain Analysis
- 2.9. Cost Structure Analysis
- 2.10. Marketing Strategy
- 2.11. Russia-Ukraine War Impact Analysis
- 2.12. Opportunity Map Analysis
- 2.13. Market Competition Scenario Analysis
- 2.14. Product Life Cycle Analysis
- 2.15. Opportunity Orbits
- 2.16. Manufacturer Intensity Map
- 2.17. Major Companies sales by Value & Volume
- 2.1. Bacille Calmette-Guerin Vaccine Market Dynamics
- 3. Global Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, 2016-2032
- 3.1. Global Bacille Calmette-Guerin Vaccine Market Analysis, 2016-2021
- 3.2. Global Bacille Calmette-Guerin Vaccine Market Opportunity and Forecast, 2023-2032
- 3.3. Global Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By Age Group, 2016-2032
- 3.3.1. Global Bacille Calmette-Guerin Vaccine Market Analysis by Age Group: Introduction
- 3.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Age Group, 2016-2032
- 3.3.3. Pediatrics
- 3.3.4. Adults
- 3.4. Global Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By Application, 2016-2032
- 3.4.1. Global Bacille Calmette-Guerin Vaccine Market Analysis by Application: Introduction
- 3.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Application, 2016-2032
- 3.4.3. Tuberculosis
- 3.4.4. Bladder cancer
- 3.5. Global Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By End-use, 2016-2032
- 3.5.1. Global Bacille Calmette-Guerin Vaccine Market Analysis by End-use: Introduction
- 3.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-use, 2016-2032
- 3.5.3. Hospitals
- 3.5.4. Clinics
- 4. North America Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, 2016-2032
- 4.1. North America Bacille Calmette-Guerin Vaccine Market Analysis, 2016-2021
- 4.2. North America Bacille Calmette-Guerin Vaccine Market Opportunity and Forecast, 2023-2032
- 4.3. North America Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By Age Group, 2016-2032
- 4.3.1. North America Bacille Calmette-Guerin Vaccine Market Analysis by Age Group: Introduction
- 4.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Age Group, 2016-2032
- 4.3.3. Pediatrics
- 4.3.4. Adults
- 4.4. North America Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By Application, 2016-2032
- 4.4.1. North America Bacille Calmette-Guerin Vaccine Market Analysis by Application: Introduction
- 4.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Application, 2016-2032
- 4.4.3. Tuberculosis
- 4.4.4. Bladder cancer
- 4.5. North America Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By End-use, 2016-2032
- 4.5.1. North America Bacille Calmette-Guerin Vaccine Market Analysis by End-use: Introduction
- 4.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-use, 2016-2032
- 4.5.3. Hospitals
- 4.5.4. Clinics
- 4.6. North America Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 4.6.1. North America Bacille Calmette-Guerin Vaccine Market Analysis by Country : Introduction
- 4.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 4.6.2.1. The US
- 4.6.2.2. Canada
- 4.6.2.3. Mexico
- 5. Western Europe Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, 2016-2032
- 5.1. Western Europe Bacille Calmette-Guerin Vaccine Market Analysis, 2016-2021
- 5.2. Western Europe Bacille Calmette-Guerin Vaccine Market Opportunity and Forecast, 2023-2032
- 5.3. Western Europe Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By Age Group, 2016-2032
- 5.3.1. Western Europe Bacille Calmette-Guerin Vaccine Market Analysis by Age Group: Introduction
- 5.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Age Group, 2016-2032
- 5.3.3. Pediatrics
- 5.3.4. Adults
- 5.4. Western Europe Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By Application, 2016-2032
- 5.4.1. Western Europe Bacille Calmette-Guerin Vaccine Market Analysis by Application: Introduction
- 5.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Application, 2016-2032
- 5.4.3. Tuberculosis
- 5.4.4. Bladder cancer
- 5.5. Western Europe Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By End-use, 2016-2032
- 5.5.1. Western Europe Bacille Calmette-Guerin Vaccine Market Analysis by End-use: Introduction
- 5.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-use, 2016-2032
- 5.5.3. Hospitals
- 5.5.4. Clinics
- 5.6. Western Europe Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 5.6.1. Western Europe Bacille Calmette-Guerin Vaccine Market Analysis by Country : Introduction
- 5.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 5.6.2.1. Germany
- 5.6.2.2. France
- 5.6.2.3. The UK
- 5.6.2.4. Spain
- 5.6.2.5. Italy
- 5.6.2.6. Portugal
- 5.6.2.7. Ireland
- 5.6.2.8. Austria
- 5.6.2.9. Switzerland
- 5.6.2.10. Benelux
- 5.6.2.11. Nordic
- 5.6.2.12. Rest of Western Europe
- 6. Eastern Europe Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, 2016-2032
- 6.1. Eastern Europe Bacille Calmette-Guerin Vaccine Market Analysis, 2016-2021
- 6.2. Eastern Europe Bacille Calmette-Guerin Vaccine Market Opportunity and Forecast, 2023-2032
- 6.3. Eastern Europe Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By Age Group, 2016-2032
- 6.3.1. Eastern Europe Bacille Calmette-Guerin Vaccine Market Analysis by Age Group: Introduction
- 6.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Age Group, 2016-2032
- 6.3.3. Pediatrics
- 6.3.4. Adults
- 6.4. Eastern Europe Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By Application, 2016-2032
- 6.4.1. Eastern Europe Bacille Calmette-Guerin Vaccine Market Analysis by Application: Introduction
- 6.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Application, 2016-2032
- 6.4.3. Tuberculosis
- 6.4.4. Bladder cancer
- 6.5. Eastern Europe Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By End-use, 2016-2032
- 6.5.1. Eastern Europe Bacille Calmette-Guerin Vaccine Market Analysis by End-use: Introduction
- 6.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-use, 2016-2032
- 6.5.3. Hospitals
- 6.5.4. Clinics
- 6.6. Eastern Europe Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 6.6.1. Eastern Europe Bacille Calmette-Guerin Vaccine Market Analysis by Country : Introduction
- 6.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 6.6.2.1. Russia
- 6.6.2.2. Poland
- 6.6.2.3. The Czech Republic
- 6.6.2.4. Greece
- 6.6.2.5. Rest of Eastern Europe
- 7. APAC Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, 2016-2032
- 7.1. APAC Bacille Calmette-Guerin Vaccine Market Analysis, 2016-2021
- 7.2. APAC Bacille Calmette-Guerin Vaccine Market Opportunity and Forecast, 2023-2032
- 7.3. APAC Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By Age Group, 2016-2032
- 7.3.1. APAC Bacille Calmette-Guerin Vaccine Market Analysis by Age Group: Introduction
- 7.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Age Group, 2016-2032
- 7.3.3. Pediatrics
- 7.3.4. Adults
- 7.4. APAC Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By Application, 2016-2032
- 7.4.1. APAC Bacille Calmette-Guerin Vaccine Market Analysis by Application: Introduction
- 7.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Application, 2016-2032
- 7.4.3. Tuberculosis
- 7.4.4. Bladder cancer
- 7.5. APAC Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By End-use, 2016-2032
- 7.5.1. APAC Bacille Calmette-Guerin Vaccine Market Analysis by End-use: Introduction
- 7.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-use, 2016-2032
- 7.5.3. Hospitals
- 7.5.4. Clinics
- 7.6. APAC Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 7.6.1. APAC Bacille Calmette-Guerin Vaccine Market Analysis by Country : Introduction
- 7.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 7.6.2.1. China
- 7.6.2.2. Japan
- 7.6.2.3. South Korea
- 7.6.2.4. India
- 7.6.2.5. Australia & New Zeland
- 7.6.2.6. Indonesia
- 7.6.2.7. Malaysia
- 7.6.2.8. Philippines
- 7.6.2.9. Singapore
- 7.6.2.10. Thailand
- 7.6.2.11. Vietnam
- 7.6.2.12. Rest of APAC
- 8. Latin America Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, 2016-2032
- 8.1. Latin America Bacille Calmette-Guerin Vaccine Market Analysis, 2016-2021
- 8.2. Latin America Bacille Calmette-Guerin Vaccine Market Opportunity and Forecast, 2023-2032
- 8.3. Latin America Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By Age Group, 2016-2032
- 8.3.1. Latin America Bacille Calmette-Guerin Vaccine Market Analysis by Age Group: Introduction
- 8.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Age Group, 2016-2032
- 8.3.3. Pediatrics
- 8.3.4. Adults
- 8.4. Latin America Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By Application, 2016-2032
- 8.4.1. Latin America Bacille Calmette-Guerin Vaccine Market Analysis by Application: Introduction
- 8.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Application, 2016-2032
- 8.4.3. Tuberculosis
- 8.4.4. Bladder cancer
- 8.5. Latin America Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By End-use, 2016-2032
- 8.5.1. Latin America Bacille Calmette-Guerin Vaccine Market Analysis by End-use: Introduction
- 8.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-use, 2016-2032
- 8.5.3. Hospitals
- 8.5.4. Clinics
- 8.6. Latin America Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 8.6.1. Latin America Bacille Calmette-Guerin Vaccine Market Analysis by Country : Introduction
- 8.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 8.6.2.1. Brazil
- 8.6.2.2. Colombia
- 8.6.2.3. Chile
- 8.6.2.4. Argentina
- 8.6.2.5. Costa Rica
- 8.6.2.6. Rest of Latin America
- 9. Middle East & Africa Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, 2016-2032
- 9.1. Middle East & Africa Bacille Calmette-Guerin Vaccine Market Analysis, 2016-2021
- 9.2. Middle East & Africa Bacille Calmette-Guerin Vaccine Market Opportunity and Forecast, 2023-2032
- 9.3. Middle East & Africa Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By Age Group, 2016-2032
- 9.3.1. Middle East & Africa Bacille Calmette-Guerin Vaccine Market Analysis by Age Group: Introduction
- 9.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Age Group, 2016-2032
- 9.3.3. Pediatrics
- 9.3.4. Adults
- 9.4. Middle East & Africa Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By Application, 2016-2032
- 9.4.1. Middle East & Africa Bacille Calmette-Guerin Vaccine Market Analysis by Application: Introduction
- 9.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Application, 2016-2032
- 9.4.3. Tuberculosis
- 9.4.4. Bladder cancer
- 9.5. Middle East & Africa Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By End-use, 2016-2032
- 9.5.1. Middle East & Africa Bacille Calmette-Guerin Vaccine Market Analysis by End-use: Introduction
- 9.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-use, 2016-2032
- 9.5.3. Hospitals
- 9.5.4. Clinics
- 9.6. Middle East & Africa Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 9.6.1. Middle East & Africa Bacille Calmette-Guerin Vaccine Market Analysis by Country : Introduction
- 9.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 9.6.2.1. Algeria
- 9.6.2.2. Egypt
- 9.6.2.3. Israel
- 9.6.2.4. Kuwait
- 9.6.2.5. Nigeria
- 9.6.2.6. Saudi Arabia
- 9.6.2.7. South Africa
- 9.6.2.8. Turkey
- 9.6.2.9. The UAE
- 9.6.2.10. Rest of MEA
- 10. Global Bacille Calmette-Guerin Vaccine Market Analysis, Opportunity and Forecast, By Region , 2016-2032
- 10.1. Global Bacille Calmette-Guerin Vaccine Market Analysis by Region : Introduction
- 10.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Region , 2016-2032
- 10.2.1. North America
- 10.2.2. Western Europe
- 10.2.3. Eastern Europe
- 10.2.4. APAC
- 10.2.5. Latin America
- 10.2.6. Middle East & Africa
- 11. Global Bacille Calmette-Guerin Vaccine Market Competitive Landscape, Market Share Analysis, and Company Profiles
- 11.1. Market Share Analysis
- 11.2. Company Profiles
- 11.3. AJ Biologics Sdn Bhd
- 11.3.1. Company Overview
- 11.3.2. Financial Highlights
- 11.3.3. Product Portfolio
- 11.3.4. SWOT Analysis
- 11.3.5. Key Strategies and Developments
- 11.4. BCG Vaccine Laboratory
- 11.4.1. Company Overview
- 11.4.2. Financial Highlights
- 11.4.3. Product Portfolio
- 11.4.4. SWOT Analysis
- 11.4.5. Key Strategies and Developments
- 11.5. Biomed Lublin S.A.
- 11.5.1. Company Overview
- 11.5.2. Financial Highlights
- 11.5.3. Product Portfolio
- 11.5.4. SWOT Analysis
- 11.5.5. Key Strategies and Developments
- 11.6. China National group corporation (Sinopharm)
- 11.6.1. Company Overview
- 11.6.2. Financial Highlights
- 11.6.3. Product Portfolio
- 11.6.4. SWOT Analysis
- 11.6.5. Key Strategies and Developments
- 11.7. GSBPL
- 11.7.1. Company Overview
- 11.7.2. Financial Highlights
- 11.7.3. Product Portfolio
- 11.7.4. SWOT Analysis
- 11.7.5. Key Strategies and Developments
- 11.8. Intervax Ltd.
- 11.8.1. Company Overview
- 11.8.2. Financial Highlights
- 11.8.3. Product Portfolio
- 11.8.4. SWOT Analysis
- 11.8.5. Key Strategies and Developments
- 11.9. Japan BCG Laboratory
- 11.9.1. Company Overview
- 11.9.2. Financial Highlights
- 11.9.3. Product Portfolio
- 11.9.4. SWOT Analysis
- 11.9.5. Key Strategies and Developments
- 11.10. Merck & Co., Inc.
- 11.10.1. Company Overview
- 11.10.2. Financial Highlights
- 11.10.3. Product Portfolio
- 11.10.4. SWOT Analysis
- 11.10.5. Key Strategies and Developments
- 11.11. Microgen
- 11.11.1. Company Overview
- 11.11.2. Financial Highlights
- 11.11.3. Product Portfolio
- 11.11.4. SWOT Analysis
- 11.11.5. Key Strategies and Developments
- 11.12. Sanofi
- 11.12.1. Company Overview
- 11.12.2. Financial Highlights
- 11.12.3. Product Portfolio
- 11.12.4. SWOT Analysis
- 11.12.5. Key Strategies and Developments
- 11.13.1. Company Overview
- 11.13.2. Financial Highlights
- 11.13.3. Product Portfolio
- 11.13.4. SWOT Analysis
- 11.13.5. Key Strategies and Developments
- 11.14. Serum Institute of India Pvt. Ltd.
- 11.14.1. Company Overview
- 11.14.2. Financial Highlights
- 11.14.3. Product Portfolio
- 11.14.4. SWOT Analysis
- 11.14.5. Key Strategies and Developments
- 11.15. Taj Pharmaceuticals Limited
- 11.15.1. Company Overview
- 11.15.2. Financial Highlights
- 11.15.3. Product Portfolio
- 11.15.4. SWOT Analysis
- 11.15.5. Key Strategies and Developments
- 11.16. Torlak Institute of Virology
- 11.16.1. Company Overview
- 11.16.2. Financial Highlights
- 11.16.3. Product Portfolio
- 11.16.4. SWOT Analysis
- 11.16.5. Key Strategies and Developments
- 11.17. Zydus Group
- 11.17.1. Company Overview
- 11.17.2. Financial Highlights
- 11.17.3. Product Portfolio
- 11.17.4. SWOT Analysis
- 11.17.5. Key Strategies and Developments
- 12. Assumptions and Acronyms
- 13. Research Methodology
- 14. Contact
"
- List of Figures
- "
- Figure 1: Global Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by Age Group in 2022
- Figure 2: Global Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by Age Group, 2016-2032
- Figure 3: Global Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by Applicationin 2022
- Figure 4: Global Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by Application, 2016-2032
- Figure 5: Global Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by End-usein 2022
- Figure 6: Global Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by End-use, 2016-2032
- Figure 7: Global Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by Region in 2022
- Figure 8: Global Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by Region, 2016-2032
- Figure 9: Global Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) (2016-2032)
- Figure 10: Global Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Figure 11: Global Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Age Group (2016-2032)
- Figure 12: Global Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Figure 13: Global Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
- Figure 14: Global Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
- Figure 15: Global Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Age Group (2016-2032)
- Figure 16: Global Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Figure 17: Global Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
- Figure 18: Global Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Region (2016-2032)
- Figure 19: Global Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Age Group (2016-2032)
- Figure 20: Global Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Application (2016-2032)
- Figure 21: Global Bacille Calmette-Guerin Vaccine Market Market Share Comparison by End-use (2016-2032)
- Figure 22: North America Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by Age Groupin 2022
- Figure 23: North America Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by Age Group, 2016-2032
- Figure 24: North America Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by Applicationin 2022
- Figure 25: North America Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by Application, 2016-2032
- Figure 26: North America Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by End-usein 2022
- Figure 27: North America Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by End-use, 2016-2032
- Figure 28: North America Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 29: North America Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 30: North America Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) (2016-2032)
- Figure 31: North America Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 32: North America Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Age Group (2016-2032)
- Figure 33: North America Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Figure 34: North America Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
- Figure 35: North America Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 36: North America Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Age Group (2016-2032)
- Figure 37: North America Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Figure 38: North America Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
- Figure 39: North America Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Country (2016-2032)
- Figure 40: North America Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Age Group (2016-2032)
- Figure 41: North America Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Application (2016-2032)
- Figure 42: North America Bacille Calmette-Guerin Vaccine Market Market Share Comparison by End-use (2016-2032)
- Figure 43: Western Europe Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by Age Groupin 2022
- Figure 44: Western Europe Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by Age Group, 2016-2032
- Figure 45: Western Europe Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by Applicationin 2022
- Figure 46: Western Europe Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by Application, 2016-2032
- Figure 47: Western Europe Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by End-usein 2022
- Figure 48: Western Europe Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by End-use, 2016-2032
- Figure 49: Western Europe Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 50: Western Europe Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 51: Western Europe Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) (2016-2032)
- Figure 52: Western Europe Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 53: Western Europe Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Age Group (2016-2032)
- Figure 54: Western Europe Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Figure 55: Western Europe Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
- Figure 56: Western Europe Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 57: Western Europe Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Age Group (2016-2032)
- Figure 58: Western Europe Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Figure 59: Western Europe Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
- Figure 60: Western Europe Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Country (2016-2032)
- Figure 61: Western Europe Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Age Group (2016-2032)
- Figure 62: Western Europe Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Application (2016-2032)
- Figure 63: Western Europe Bacille Calmette-Guerin Vaccine Market Market Share Comparison by End-use (2016-2032)
- Figure 64: Eastern Europe Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by Age Groupin 2022
- Figure 65: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by Age Group, 2016-2032
- Figure 66: Eastern Europe Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by Applicationin 2022
- Figure 67: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by Application, 2016-2032
- Figure 68: Eastern Europe Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by End-usein 2022
- Figure 69: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by End-use, 2016-2032
- Figure 70: Eastern Europe Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 71: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 72: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) (2016-2032)
- Figure 73: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 74: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Age Group (2016-2032)
- Figure 75: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Figure 76: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
- Figure 77: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 78: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Age Group (2016-2032)
- Figure 79: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Figure 80: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
- Figure 81: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Country (2016-2032)
- Figure 82: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Age Group (2016-2032)
- Figure 83: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Application (2016-2032)
- Figure 84: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Share Comparison by End-use (2016-2032)
- Figure 85: APAC Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by Age Groupin 2022
- Figure 86: APAC Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by Age Group, 2016-2032
- Figure 87: APAC Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by Applicationin 2022
- Figure 88: APAC Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by Application, 2016-2032
- Figure 89: APAC Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by End-usein 2022
- Figure 90: APAC Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by End-use, 2016-2032
- Figure 91: APAC Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 92: APAC Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 93: APAC Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) (2016-2032)
- Figure 94: APAC Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 95: APAC Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Age Group (2016-2032)
- Figure 96: APAC Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Figure 97: APAC Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
- Figure 98: APAC Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 99: APAC Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Age Group (2016-2032)
- Figure 100: APAC Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Figure 101: APAC Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
- Figure 102: APAC Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Country (2016-2032)
- Figure 103: APAC Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Age Group (2016-2032)
- Figure 104: APAC Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Application (2016-2032)
- Figure 105: APAC Bacille Calmette-Guerin Vaccine Market Market Share Comparison by End-use (2016-2032)
- Figure 106: Latin America Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by Age Groupin 2022
- Figure 107: Latin America Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by Age Group, 2016-2032
- Figure 108: Latin America Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by Applicationin 2022
- Figure 109: Latin America Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by Application, 2016-2032
- Figure 110: Latin America Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by End-usein 2022
- Figure 111: Latin America Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by End-use, 2016-2032
- Figure 112: Latin America Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 113: Latin America Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 114: Latin America Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) (2016-2032)
- Figure 115: Latin America Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 116: Latin America Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Age Group (2016-2032)
- Figure 117: Latin America Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Figure 118: Latin America Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
- Figure 119: Latin America Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 120: Latin America Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Age Group (2016-2032)
- Figure 121: Latin America Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Figure 122: Latin America Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
- Figure 123: Latin America Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Country (2016-2032)
- Figure 124: Latin America Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Age Group (2016-2032)
- Figure 125: Latin America Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Application (2016-2032)
- Figure 126: Latin America Bacille Calmette-Guerin Vaccine Market Market Share Comparison by End-use (2016-2032)
- Figure 127: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by Age Groupin 2022
- Figure 128: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by Age Group, 2016-2032
- Figure 129: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by Applicationin 2022
- Figure 130: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by Application, 2016-2032
- Figure 131: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by End-usein 2022
- Figure 132: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by End-use, 2016-2032
- Figure 133: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 134: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 135: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) (2016-2032)
- Figure 136: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 137: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Age Group (2016-2032)
- Figure 138: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Figure 139: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
- Figure 140: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 141: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Age Group (2016-2032)
- Figure 142: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Figure 143: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
- Figure 144: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Country (2016-2032)
- Figure 145: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Age Group (2016-2032)
- Figure 146: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Application (2016-2032)
- Figure 147: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Share Comparison by End-use (2016-2032)
"
- List of Tables
- "
- Table 1: Global Bacille Calmette-Guerin Vaccine Market Market Comparison by Age Group (2016-2032)
- Table 2: Global Bacille Calmette-Guerin Vaccine Market Market Comparison by Application (2016-2032)
- Table 3: Global Bacille Calmette-Guerin Vaccine Market Market Comparison by End-use (2016-2032)
- Table 4: Global Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Table 5: Global Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) (2016-2032)
- Table 6: Global Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Table 7: Global Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Age Group (2016-2032)
- Table 8: Global Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Table 9: Global Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
- Table 10: Global Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
- Table 11: Global Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Age Group (2016-2032)
- Table 12: Global Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Table 13: Global Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
- Table 14: Global Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Region (2016-2032)
- Table 15: Global Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Age Group (2016-2032)
- Table 16: Global Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Application (2016-2032)
- Table 17: Global Bacille Calmette-Guerin Vaccine Market Market Share Comparison by End-use (2016-2032)
- Table 18: North America Bacille Calmette-Guerin Vaccine Market Market Comparison by Application (2016-2032)
- Table 19: North America Bacille Calmette-Guerin Vaccine Market Market Comparison by End-use (2016-2032)
- Table 20: North America Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 21: North America Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) (2016-2032)
- Table 22: North America Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 23: North America Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Age Group (2016-2032)
- Table 24: North America Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Table 25: North America Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
- Table 26: North America Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 27: North America Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Age Group (2016-2032)
- Table 28: North America Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Table 29: North America Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
- Table 30: North America Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Country (2016-2032)
- Table 31: North America Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Age Group (2016-2032)
- Table 32: North America Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Application (2016-2032)
- Table 33: North America Bacille Calmette-Guerin Vaccine Market Market Share Comparison by End-use (2016-2032)
- Table 34: Western Europe Bacille Calmette-Guerin Vaccine Market Market Comparison by Age Group (2016-2032)
- Table 35: Western Europe Bacille Calmette-Guerin Vaccine Market Market Comparison by Application (2016-2032)
- Table 36: Western Europe Bacille Calmette-Guerin Vaccine Market Market Comparison by End-use (2016-2032)
- Table 37: Western Europe Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 38: Western Europe Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) (2016-2032)
- Table 39: Western Europe Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 40: Western Europe Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Age Group (2016-2032)
- Table 41: Western Europe Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Table 42: Western Europe Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
- Table 43: Western Europe Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 44: Western Europe Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Age Group (2016-2032)
- Table 45: Western Europe Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Table 46: Western Europe Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
- Table 47: Western Europe Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Country (2016-2032)
- Table 48: Western Europe Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Age Group (2016-2032)
- Table 49: Western Europe Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Application (2016-2032)
- Table 50: Western Europe Bacille Calmette-Guerin Vaccine Market Market Share Comparison by End-use (2016-2032)
- Table 51: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Comparison by Age Group (2016-2032)
- Table 52: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Comparison by Application (2016-2032)
- Table 53: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Comparison by End-use (2016-2032)
- Table 54: Eastern Europe Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 55: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) (2016-2032)
- Table 56: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 57: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Age Group (2016-2032)
- Table 58: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Table 59: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
- Table 60: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 61: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Age Group (2016-2032)
- Table 62: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Table 63: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
- Table 64: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Country (2016-2032)
- Table 65: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Age Group (2016-2032)
- Table 66: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Application (2016-2032)
- Table 67: Eastern Europe Bacille Calmette-Guerin Vaccine Market Market Share Comparison by End-use (2016-2032)
- Table 68: APAC Bacille Calmette-Guerin Vaccine Market Market Comparison by Age Group (2016-2032)
- Table 69: APAC Bacille Calmette-Guerin Vaccine Market Market Comparison by Application (2016-2032)
- Table 70: APAC Bacille Calmette-Guerin Vaccine Market Market Comparison by End-use (2016-2032)
- Table 71: APAC Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 72: APAC Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) (2016-2032)
- Table 73: APAC Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 74: APAC Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Age Group (2016-2032)
- Table 75: APAC Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Table 76: APAC Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
- Table 77: APAC Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 78: APAC Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Age Group (2016-2032)
- Table 79: APAC Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Table 80: APAC Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
- Table 81: APAC Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Country (2016-2032)
- Table 82: APAC Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Age Group (2016-2032)
- Table 83: APAC Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Application (2016-2032)
- Table 84: APAC Bacille Calmette-Guerin Vaccine Market Market Share Comparison by End-use (2016-2032)
- Table 85: Latin America Bacille Calmette-Guerin Vaccine Market Market Comparison by Age Group (2016-2032)
- Table 86: Latin America Bacille Calmette-Guerin Vaccine Market Market Comparison by Application (2016-2032)
- Table 87: Latin America Bacille Calmette-Guerin Vaccine Market Market Comparison by End-use (2016-2032)
- Table 88: Latin America Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 89: Latin America Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) (2016-2032)
- Table 90: Latin America Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 91: Latin America Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Age Group (2016-2032)
- Table 92: Latin America Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Table 93: Latin America Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
- Table 94: Latin America Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 95: Latin America Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Age Group (2016-2032)
- Table 96: Latin America Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Table 97: Latin America Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
- Table 98: Latin America Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Country (2016-2032)
- Table 99: Latin America Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Age Group (2016-2032)
- Table 100: Latin America Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Application (2016-2032)
- Table 101: Latin America Bacille Calmette-Guerin Vaccine Market Market Share Comparison by End-use (2016-2032)
- Table 102: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Comparison by Age Group (2016-2032)
- Table 103: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Comparison by Application (2016-2032)
- Table 104: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Comparison by End-use (2016-2032)
- Table 105: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 106: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) (2016-2032)
- Table 107: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 108: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Age Group (2016-2032)
- Table 109: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Table 110: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
- Table 111: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 112: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Age Group (2016-2032)
- Table 113: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Table 114: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
- Table 115: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Country (2016-2032)
- Table 116: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Age Group (2016-2032)
- Table 117: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Share Comparison by Application (2016-2032)
- Table 118: Middle East & Africa Bacille Calmette-Guerin Vaccine Market Market Share Comparison by End-use (2016-2032)
- 1. Executive Summary
-
- AJ Biologics Sdn Bhd
- BCG Vaccine Laboratory
- Biomed Lublin S.A.
- China National Group Corporation (Sinopharm)
- GSBPL
- Intervax Ltd.
- Japan BCG Laboratory
- Merck & Co., Inc.
- Microgen
- Sanofi
- Serum Institute of India Pvt. Ltd.
- Stetens Serum Institute
- Taj Pharmaceuticals Limited
- Torlak Institute of Virology
- Zydus Group
Our Clients
View Our Licence Options
